In today’s session Alexion Pharmaceuticals, Inc. (ALXN) registered an unusually high (726) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ALXN increase. With 726 contracts traded and 12904 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ALXN170120C00125000 closed last at: $10.5 or 56.7% up. About 321,976 shares traded hands. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 13.99% since April 28, 2016 and is downtrending. It has underperformed by 19.92% the S&P500.
Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 1. They expect $1.10 earnings per share, up 30.95% or $0.26 from last year’s $0.84 per share. ALXN’s profit will be $240.78M for 27.87 P/E if the $1.10 EPS becomes a reality. After $1.18 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.78% negative EPS growth.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage
Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 16 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 80% are positive. $257 is the highest target while $82 is the lowest. The $177.47 average target is 44.73% above today’s ($122.62) stock price. Alexion Pharmaceuticals Inc. has been the topic of 41 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Overweight” rating given on Tuesday, June 7 by Morgan Stanley. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, July 13. Wedbush initiated it with “Neutral” rating and $132 target price in Friday, September 23 report. UBS maintained the stock with “Buy” rating in Thursday, February 4 report. Morgan Stanley upgraded it to “Overweight” rating and $211 target price in Friday, October 2 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Neutral” rating given on Thursday, January 7 by BTIG Research. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, July 29. On Thursday, April 7 the stock rating was initiated by BMO Capital Markets with “Market Perform”. The firm has “Neutral” rating by Credit Suisse given on Wednesday, January 20. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by BMO Capital Markets on Friday, April 29.
According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”
Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.12, from 1.19 in 2016Q1. The ratio dropped, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Bp Public Limited Co holds 0.03% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 7,000 shares. Cornerstone Advsr holds 0.08% or 654 shares in its portfolio. Aperio Grp Ltd has invested 0.06% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). State Treasurer State Of Michigan accumulated 0.07% or 77,774 shares. Wms Prtn Limited Liability Com has invested 0.03% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Gotham Asset Lc last reported 0.08% of its portfolio in the stock. Moreover, Evercore Wealth Ltd Co has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1,550 shares. Rockefeller Finance Svcs has 9,257 shares for 0.02% of their US portfolio. Alliancebernstein L P owns 2.47M shares or 0.25% of their US portfolio. Us Comml Bank De owns 49,135 shares or 0.02% of their US portfolio. California Public Employees Retirement System, a California-based fund reported 520,391 shares. Bamco Inc New York last reported 62,249 shares in the company. Bb&T Lc holds 0.02% or 8,532 shares in its portfolio. Ingalls Snyder Ltd owns 4,000 shares or 0.03% of their US portfolio. First Republic Invest Inc accumulated 11,245 shares or 0.01% of the stock.
Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 19 insider sales for $9.39 million net activity. On Monday, August 8 the insider Hallal David sold $45,530. Thiel Carsten also sold $414,945 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. On Monday, June 13 Moriarty John B sold $124,591 worth of the stock or 918 shares. 277 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $37,988 were sold by Sinha Vikas. 1,010 shares were sold by BELL LEONARD, worth $138,511 on Monday, August 8. Wagner Heidi L had sold 222 shares worth $30,445. PARVEN ALVIN S sold 15,700 shares worth $2.14 million.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $26.84 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 75.36 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.
ALXN Company Profile
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
More recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Marketwatch.com which released: “Alexion Pharma shares halted, company to delay quarterly results” on November 09, 2016. Also Businesswire.com published the news titled: “Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders …” on November 22, 2016. Prnewswire.com‘s news article titled: “Harwood Feffer LLP Announces Investigation of Alexion Pharmaceuticals, Inc.” with publication date: November 10, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.